Grupo Pardini tem 100% de trabalhos científicos aceitos no congresso mais importante do mundo de Análises Clínicas, o AACC, nos Estados Unidos

 Todos os 25 trabalhos científicos enviados pelo Grupo Pardini foram aprovados no congresso da American Association for Clinical Chemistry - AACC (Associação Americana de Química Clínica). O encontro será realizado de 4 a 8 de agosto, na cidade de Anaheim, na Califórnia (EUA).

O trabalho intitulado “Retrospective analysis of FLT3-ITD and FLT3-TKD (D835) mutations in a Brazilian cohort” ficou em terceiro lugar na categoria: Tumor Markers And Cancer Diagnostics Division e será apresentado no dia 6 de agosto, o que demonstra o reconhecimento da importância do estudo.

A AACC é uma organização global de profissionais médicos e pesquisadores dedicada à ciência de laboratório clínico e sua aplicação aos cuidados de saúde. A atuação em educação, defesa e colaboração ajuda os profissionais de laboratório a se adaptarem às mudanças e a fazer o que fazem melhor: fornecer informações e orientação vitais para que os pacientes recebam o cuidado de que precisam.

Para a coordenadora de Pesquisa e Desenvolvimento (P&D) do Grupo Pardini, Danielle Alves Gomes Zauli, a aceitação de 100% dos trabalhos é reflexo da estratégia da Companhia de investir em inovação e no capital humano.

Confira abaixo a lista completa dos trabalhos científicos enviados pelos pesquisadores do Grupo Pardini.

1- A Multi-cancer Panel Screening From Solid Tumors In A Triennium Brazilian Cohort.
2- Evaluation Between Two Lc-ms/Ms Protocols And Dimension Csa Immunoassay Method For Determination Of Cyclosporine A In Whole Blood.
3- Dried Blood Spots - Applications In Molecular Techniques.
4-standardization Of The Isolation Of Umbilical Cord Cells Under Xenofree Conditions By Explant Method And Evalution Of Cell Viability After Cryopreservation.
5- Determination Of Sirolimus In Whole Blood By Lc-ms/Ms For Therapeutic Drug Monitoring.
6- Peripheral Biomarkers As Predictors Of Cognitive Decline In An Elderly Population From Brazil.
7- Evaluation Of Immunologic Methods To Detect Leishmania Donovani.
8- A Possible Algorithm For Diagnosis And Screening Of Clostridium Difficile.
9- Orthogonal Confirmation For Ngs Should Not Be Completely Eliminated Into Clinical Practice For Amplicon-based Ngs Panels.
10- Rapid Determination Of Pantothenic Acid In Human Serum By Lc-ms/Ms.
11- Simple And Fast Determination Of Cyclosporine A In Whole Blood By Lc-ms/Ms For Therapeutic Drug Monitoring.
12- Development And Validation Of Tacrolimus In Whole Blood By Lc-ms/Ms.
13- Investigation Of Copy Number Variation (Cnv) Alterations In Patients With Autism Spectrum Disorder (Asd) In A Brazilian Cohort.
14- Validation Of A Ngs Pan Panel For Cardiomyopathies.
15- Tuberous Sclerosis Complex (Tsc) Screening Using Ngs And Mlpa In Brazilian Patients.
16- Molecular Monitoring Of P190bcr-abl1 Levels Should Not Be Neglected In Chronic Myeloid Leukemia (Cml) Patients Treated With Tyrosin Kinase Inibitors (Tkis).
17- Retrospective Analysis Of Flt3-itd And Flt3-tkd (D835) Mutations In A Brazilian Cohort.
18- H1n1: A Retrospective Study From Brazilian Landscape Between 2016 And 2018.
19- Tumor Mutation Burden (Tmb) In Ffpe Samples: A Pilot Study Using A Large Gene Target Sequencing Panel.
20- Evaluation Of Minimally-invasive Detection Assays For Pharmacogenetics Applications.
21- Zdc (Zika, Dengue And Chikungunya): The Performance Of Kit For Multiplex Detection In Brazilian Laboratory.
22- Performance Of Improved Rt-qpcr Assays To Accurately Monitor Bcr-abl1 Major Fusion Transcripts In Chronic Myeloid Leukemia (Cml): Transition From Mr4.5 To 4.7.
23- Hla-tagging Snp May Not Be Suitable For Dq2.5 Risk Prediction For Brazilian Celiac Population.
24- Saint Louis Encephalitis Virus (Slev): Analytical Validation Of Molecular Method For Rapid Detection For Control Measures And Epidemiological Studies.
25- Validation Of Interphase Fluorescence In Situ Hybridization (Fish) Panel For Detection Of The Chromosomal Abnormalities In Patients With Multiple Myeloma.

 
Fonte: Árvore.